Abbott Laboratories


  • WASHINGTON, Nov 5- The U.S. Supreme Court on Tuesday heard arguments in a case of warring legal doctrines raised by a heart pacemaker patent fight between giant medical devices company Medtronic Inc and privately owned Mirowski Family Ventures LLC.

  • Get over taper talk. Pro offers 3 Fed-proof stocks Wednesday, 30 Oct 2013 | 1:01 PM ET

    Westwood Holding Group’s Mark Freeman has investment recommendations for companies less dependent on Fed stimulus.

  • Oct 25- The U.S. Food and Drug Administration has approved Abbott Laboratories' MitraClip medical device, used to stop heart valve leakage in patients deemed unable to endure valve repair through open heart surgery, the company said on Friday. "We think longer term in the U.S., could be a $500 million product," said RBC Capital Markets analyst Glenn Novarro.

  • Abbott says FDA approved heart valve medical device Friday, 25 Oct 2013 | 9:19 AM ET

    Oct 25- Abbott Laboratories said on Friday that the U.S. Food and Drug Administration approved its MitraClip medical device, used to stop heart valve leakage. A slim majority of advisers to the FDA had recommended approval of the implantable heart device, as some had questioned whether it would be effective for its intended use.

  • Cramer: 12 things you missed in the market Wednesday, 16 Oct 2013 | 6:03 PM ET

    Has Washington distracted you from these money making developments?

  • Midday movers: Regeneron, Abbott, Sprint & more Wednesday, 16 Oct 2013 | 12:05 PM ET

    Take a look at some of Wednesday's midday movers:

  • Futures higher amid hopes for debt deal; BAC climbs Wednesday, 16 Oct 2013 | 9:14 AM ET

    U.S. stock index futures pointed to a higher open on Wednesday, with lawmakers looking to strike a deal to lift the country's borrowing limit before Thursday's deadline.

  • Washington deadline could be nail biter for markets Tuesday, 15 Oct 2013 | 8:09 PM ET
    Traders on the floor of the New York Stock Exchange.

    With a deadline hanging over Congress, stocks could be whipped by headlines from Washington but should ultimately be able to limp through the drama.

  • Are these 3 companies next to lift their dividend? Tuesday, 17 Sep 2013 | 1:16 PM ET
    A jogger runs past signage displayed at the Microsoft Corp. campus in Redmond, Washington.

    On the heels of Microsoft boosting its dividend and renewing its buyback, there are a host of other companies that could be candidates for the same.

  • These biotech names are ripe for takeover: Cramer Tuesday, 27 Aug 2013 | 7:19 PM ET

    We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.

  • China fines milk powder makers for price fixing Wednesday, 7 Aug 2013 | 5:24 AM ET
    Dumex baby formula, which uses the New Zealand dairy company Fonterra as its raw material supplier, at a store in Yichang, in central China's Hubei province on August 5, 2013.

    China fined six companies including New Zealand dairy giant Fonterra a total of $110 million following an investigation into price fixing and anti-competitive practices by foreign baby formula makers.

  • Pfizer earnings beat forecasts as it plans split Tuesday, 30 Jul 2013 | 6:09 AM ET

    Pfizer reported earnings slightly ahead of forecasts, as the largest U.S. drugmaker lines up a business split that could lead to the spin-off of its generics division.

  • China blocks Glaxo finance head from leaving Wednesday, 17 Jul 2013 | 11:31 AM ET

    China is preventing a GlaxoSmithKline executive from leaving the country as police accuse the British drugmaker of bribing officials and doctors, the drugmaker says.

  • Futures turn higher after release of Bernanke testimony Wednesday, 17 Jul 2013 | 8:41 AM ET

    U.S. stock index futures turned slightly positive Wednesday after Fed Chairman Ben Bernanke reiterated the central bank's plan to start paring back its bond-purchase program later this year, but said that could change if the economic outlook shifted.

  • China Syndrome: Foreign crackdown no coincidence Friday, 12 Jul 2013 | 5:00 AM ET

    China is using "concerted" probes of foreign baby formula, pharmaceutical and packaging companies to bolster domestic firms, according to observers.

  • Gov. Quinn: Why Illinois is top state for business Tuesday, 9 Jul 2013 | 10:30 AM ET
    Illinois Gov. Pat Quinn

    At the heart of Illinois is Chicago, the nation’s third-largest metro area and home to world-class institutions including the Chicago Symphony and the Art Institute of Chicago.

  • Chinese Shell Out Big Bucks for Imported Baby Goods Sunday, 7 Jul 2013 | 10:11 PM ET

    Chinese authorities are investigating a possible price-fixing for infant formula milk, as consumers pay premiums for imported products on fears that local ones may be contaminated.

  • Employer Mandate Delay Hits Reform, Not Stocks Wednesday, 3 Jul 2013 | 3:49 PM ET

    The delay of Obamacare's employer mandate isn't a blow to health-care stocks. However, the outlook for reform is another matter.

  • Jim Cramer’s Down and Out Turnaround Play Friday, 17 May 2013 | 6:29 PM ET

    Cramer has been looking at long-term losers to see if any show potential. He’s found something.

  • Cramer: Break-Up Could Boost This Stock 19% Friday, 17 May 2013 | 6:02 PM ET

    Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.

Most Popular Video

Wednesday, 16 Apr 2014 | 4:40 AM ET

Loyalists around the world have embraced it as the cryptocurrency of the future, but some big names on the street differ widely in their beliefs about bitcoin. The Oracle of Omaha thinks it's a "joke." Tech entrepreneur Marc Andreessen counters that Buffett is out of touch, while bitcoin believers like Jonathan Rumion fully embrace the digital currency by buying groceries with bitcoin and even getting paid in bitcoin. CNBC's Mary Thompson reports.

Wednesday, 16 Apr 2014 | 3:00 AM ET

European shares opened higher on Wednesday as better-than-expected Chinese growth data buoyed sentiment.

Wednesday, 16 Apr 2014 | 2:00 AM ET

Brady Dougan, CEO of Credit Suisse, says the bank's fixed income business is "strong", while the investment banking arm has performed well.